In February 2026, a study published in JAMA Psychiatry tracked 200 military veterans with combat-related PTSD who received a single treatment with a psychedelic compound called ibogaine. At the three-month follow-up, 67% no longer met the diagnostic criteria for PTSD. Eighty-one percent reported clinically significant improvement.
In the United States, ibogaine is a Schedule I controlled substance — categorized as having "no accepted medical use" and a "high potential for abuse." Americans who want access to treatment are traveling to clinics in Mexico.
What Ibogaine Is
Ibogaine is a psychoactive alkaloid extracted from the root bark of Tabernanthe iboga, a shrub native to Central and West Africa. For generations, the Bwiti tradition in Gabon has used ibogaine in spiritual initiation and healing ceremonies. Its entry into Western medicine began with something that researchers noticed almost by accident: people who took ibogaine in ceremonial contexts reported that their cravings for opioids or stimulants had disappeared — often dramatically, and often after a single session.
What distinguishes ibogaine from other psychedelics is both its duration and its character. The experience lasts 24 to 48 hours — significantly longer than psilocybin or LSD — and many participants describe it not as a visual or recreational experience but as an intense, involuntary "life review." Images and memories surface. Events and patterns are revisited. People frequently emerge from the experience reporting insights about the roots of their compulsive behavior that feel different from anything conventional therapy has produced.
What the Research Shows
The JAMA Psychiatry veteran study is among the most significant recent data points. It joins earlier work by Dr. Nolan Williams at Stanford, whose research in 2024 and 2025 documented dramatic improvements in veterans with both combat PTSD and traumatic brain injury following ibogaine treatment — improvements that held at follow-up and were accompanied by measurable changes in brain structure visible on MRI scans.
For opioid addiction specifically, observational studies conducted primarily in clinics outside the US — in Mexico, New Zealand, and Brazil — have documented abstinence rates ranging from 23 to 55% at one year. Those numbers are significantly higher than most conventional addiction treatments, which typically report 20 to 30% abstinence rates at twelve months. The effect appears to work differently from medication-assisted treatments like suboxone, which manage withdrawal and craving on an ongoing basis — ibogaine appears to interrupt the underlying circuit in a more fundamental way, at least for some patients.
The science behind this is still being developed. Ibogaine interacts with multiple neurotransmitter systems simultaneously — NMDA, kappa-opioid, serotonin, sigma receptors — and increases neuroplasticity in ways that may allow the brain to effectively "reset" patterns of dependence. Researchers are working to isolate which aspects of the mechanism account for its effects.
The Safety Problem That Kept It Off Limits
Ibogaine's therapeutic potential has been understood for decades. The reason it remained Schedule I while other psychedelics like psilocybin began moving toward legalization is straightforward: cardiac risk.
Ibogaine causes QT prolongation — a change in the heart's electrical rhythm that can trigger fatal arrhythmias. People have died during ibogaine treatment. The risk appears to be manageable with proper medical screening, cardiac monitoring during the session, and appropriate protocols — but it requires a clinical setting, not a ceremonial one, and not a retreat without medical oversight.
Synthetic analogues that replicate ibogaine's anti-addictive effects without the cardiac risk are currently in development, but human trials are still early.
Why 2026 Changed the Conversation
In April 2026, President Trump signed an executive order directing federal agencies to accelerate research into psychedelic compounds, including ibogaine, as potential treatments for addiction, PTSD, and traumatic brain injury. The order specifically recognized the compound's potential for veteran treatment — a priority that has bipartisan support in a way that broader drug policy reform often doesn't.
Texas had already made a substantial move: a $50 million public-private partnership launched in 2025 to fund FDA-regulated clinical trials, with inpatient settings and mandatory cardiac monitoring. Several other states are watching the Texas model.
Ibogaine went from fringe psychedelic to executive-order-level federal priority in the span of roughly 18 months — accelerated partly by the opioid crisis numbers that have not improved, and partly by veterans who have experienced the treatment and are talking about it publicly in ways that politicians cannot ignore. Joe Rogan brought it up in a conversation with Trump in the Oval Office.
It is still Schedule I. It is still illegal to prescribe or administer in the United States. And Americans are still getting on planes to Mexico to access it, betting that the legal framework will eventually catch up to what the research is showing.
